Skip to main content
SpringerLink
Log in

Hereditary Issues In Ovarian Cancer

  • Chapter
Molecular Pathology of Gynecologic Cancer

Part of the book series: Current Clinical Oncology ((CCO))

  • 922 Accesses

Abstract

Epithelial ovarian cancer (EOC) is the leading cause of gynecological cancer deaths, although it accounts for only about one-quarter of all gynecological malignancies (1, 2). A woman’s lifetime risk of ovarian cancer is about 1 in 70. In the year 2004, the American Cancer Society estimated that 25,580 women would be diagnosed with ovarian cancer in the United States, and that 16,090 would die of this disease (3).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Tortolero-Luna G, Mitchell MF, Rhodes-Morris HE. Epidemiology and screening of ovarian cancer. Obstet Gynecol Clin NA 1994; 21: 1–23.

    CAS  Google Scholar 

  2. Baker TR, Piver MS. Etiology, biology, and epidemiology of ovarian cancer. Seminars Surg Oncol 1994; 10: 242–248.

    CAS  Google Scholar 

  3. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics 2004. CA Cancer J Clin 2004; 54(1): 8–29.

    PubMed  Google Scholar 

  4. Lynch HT, Shaw MW, Magnuson CW, Larsen AL, Krush AJ. Hereditary factors in cancer. Study of two large midwestern kindreds. Arch Intern Med 1966; 117(2): 206–212.

    PubMed  CAS  Google Scholar 

  5. Koch M, Gaedke H, Jenkins H. Family history of ovarian cancer patients: a case-control study. Int J Epidemiol 1989; 18(4): 782–785.

    PubMed  CAS  Google Scholar 

  6. Hartge P, Schiffman MH, Hoover R, McGowan L, Lesher L, Norris HJ. A case-control study of epithelial ovarian cancer. Am J Obstet Gynecol 1989; 161(1): 10–16.

    PubMed  CAS  Google Scholar 

  7. Schildkraut JM, Thompson WD. Familial ovarian cancer: a population-based case-control study. Am J Epidemiol 1988; 128(3): 456–466.

    PubMed  CAS  Google Scholar 

  8. Stratton JF, Pharoah P, Smith SK, Easton D, Ponder BA. A systematic review and meta-analysis of family history and risk of ovarian cancer. Br J Obstet Gynaecol 1998; 105(5): 493–A99.

    PubMed  CAS  Google Scholar 

  9. McGowan L, Parent L, Lednar W, Norris HJ. The woman at risk for developing ovarian cancer. Gynecol Oncol 1979; 7(3): 325–344.

    PubMed  CAS  Google Scholar 

  10. Parazzini F, La Vecchia C, Negri E, Gentile A. Menstrual factors and the risk of epithelial ovarian cancer. J Clin Epidemiol 1989; 42(5): 443–448.

    PubMed  CAS  Google Scholar 

  11. Joly DJ, Lilienfeld AM, Diamond EL, Bross ID. An epidemiologic study of the relationship of reproductive experience to cancer of the ovary. Am J Epidemiol 1974; 99(3): 190–209.

    PubMed  CAS  Google Scholar 

  12. Nasca PC, Greenwald P, Chorost S, Richart R, Caputo T. An epidemiologic case-control study of ovarian cancer and reproductive factors. Am J Epidemiol 1984; 119(5): 705–713.

    PubMed  CAS  Google Scholar 

  13. Whittemore AS, Wu ML, Paffenbarger RS Jr, et al. Epithelial ovarian cancer and the ability to conceive. Cancer Res 1989; 49(14): 4047–4052.

    PubMed  CAS  Google Scholar 

  14. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. IV. The pathogenesis of epithelial ovarian cancer. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992; 136(10): 1212–1220.

    PubMed  CAS  Google Scholar 

  15. Rossing MA, Daling JR, Weiss NS, Moore DE, Self SG. Ovarian tumors in a cohort of infertile women. N Engl J Med 1994; 331(12): 771–776.

    PubMed  CAS  Google Scholar 

  16. Booth M, Beral V, Smith P. Risk factors for ovarian cancer: a case-control study. Br J Cancer 1989; 60(4): 592–598.

    PubMed  CAS  Google Scholar 

  17. Hankinson SE, Hunter DJ, Colditz GA, et al. Tubal ligation, hysterectomy, and risk of ovarian cancer. A prospective study. JAMA 1993; 270(23): 2813–2818.

    PubMed  CAS  Google Scholar 

  18. Risch HA, Marrett LD, Howe GR. Parity, contraception, infertility, and the risk of epithelial ovarian cancer. Am J Epidemiol 1994; 140(7): 585–597.

    PubMed  CAS  Google Scholar 

  19. Wu ML, Whittemore AS, Paffenbarger RS Jr, et al. Personal and environmental characteristics related to epithelial ovarian cancer. I. Reproductive and menstrual events and oral contraceptive use. Am J Epidemiol 1988; 128(6): 1216–1227.

    PubMed  CAS  Google Scholar 

  20. Rosenblatt KA, Thomas DB. Lactation and the risk of epithelial ovarian cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Epidemiol 1993; 22(2): 192–197.

    PubMed  CAS  Google Scholar 

  21. Siskind V, Green A, Bain C, Purdie D. Breastfeeding, menopause, and epithelial ovarian cancer. Epidemiology 1997; 8(2): 188–191.

    PubMed  CAS  Google Scholar 

  22. Tung KH, Goodman MT, Wu AH, et al. Reproductive factors and epithelial ovarian cancer risk by histologic type: a multiethnic case-control study. Am J Epidemiol 2003; 158(7): 629–638.

    PubMed  Google Scholar 

  23. Casagrande JT, Louie EW, Pike MC, Roy S, Ross RK, Henderson BE. “Incessant ovulation” and ovarian cancer. Lancet 1979; 2(8135): 170–173.

    PubMed  CAS  Google Scholar 

  24. Narod SA, Risch H, Moslehi R, et al. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med 1998; 339(7): 424–428.

    PubMed  CAS  Google Scholar 

  25. Ness RB, Grisso JA, Vergona R, Klapper J, Morgan M, Wheeler JE. Oral contraceptives, other methods of contraception, and risk reduction for ovarian cancer. Epidemiology 2001; 12(3): 307–312.

    PubMed  CAS  Google Scholar 

  26. The reduction in risk of ovarian cancer associated with oral-contraceptive use. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. N Engl J Med 1987; 316(11): 650–655.

    Google Scholar 

  27. Annegers JF, Strom H, Decker DG, Dockerty MB, O’Fallon WM. Ovarian cancer: incidence and case-control study. Cancer 1979; 43(2): 723–729.

    PubMed  CAS  Google Scholar 

  28. Green A, Purdie D, Bain C, et al. Tubal sterilisation, hysterectomy and decreased risk of ovarian cancer. Survey of Women’s Health Study Group. Int J Cancer 1997; 71(6): 948–951.

    PubMed  CAS  Google Scholar 

  29. Rosenblatt KA, Thomas DB. Reduced risk of ovarian cancer in women with a tubal ligation or hysterectomy. The World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives. Cancer Epidemiol Biomarkers Prev 1996; 5(11): 933–935.

    PubMed  CAS  Google Scholar 

  30. Loft A, Lidegaard O, Tabor A. Incidence of ovarian cancer after hysterectomy: a nationwide controlled follow up. Br J Obstet Gynaecol 1997; 104(11): 1296–1301.

    PubMed  CAS  Google Scholar 

  31. Amos CI, Struewing JP. Genetic epidemiology of epithelial ovarian cancer. Cancer 1993; 71(Suppl 2): 566–572.

    PubMed  CAS  Google Scholar 

  32. McGuire V, Jesser CA, Whittemore AS. Survival among US women with invasive epithelial ovarian cancer. Gynecol Oncol 2002; 84(3): 399–403.

    PubMed  Google Scholar 

  33. Averette HE, Janicek MF, Menck HR. The National Cancer Data Base report on ovarian cancer. American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1995; 76(6): 1096–1103.

    PubMed  CAS  Google Scholar 

  34. Kosary CL. FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973–1987 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina. Semin Surg Oncol 1994; 10(1): 31–46.

    PubMed  CAS  Google Scholar 

  35. Goodman MT, Howe HL, Tung KH, Hotes J, Miller BA, Coughlin SS, Chen VW. Incidence of ovarian cancer by race and ethnicity in the United States, 1992–1997. Cancer 2003; 97(Suppl 10): 2676–2685.

    PubMed  Google Scholar 

  36. Miller BA, Kolonel LN, Bernstein L, et al. (eds.). Racial/Ethnic Patterns of Cancer in the United States 1988–1992 (NIH Publication No. 96–4104). Bethesda, MD, National Institues of Health, National Cancer Institute; 1996.

    Google Scholar 

  37. Lingeman CH. Environmental factors in the etiology of carcinoma of the human ovary: a review. Am J IndMed 1983; 4(1–2): 365–379.

    CAS  Google Scholar 

  38. Beral V, Fraser P, Chilvers C. Does pregnancy protect against ovarian cancer? Lancet 1978; 1(8073): 1083–1087.

    PubMed  CAS  Google Scholar 

  39. dos Santos Silva I, Swerdlow AJ. Recent trends in incidence of and mortality from breast, ovarian and endometrial cancers in England and Wales and their relation to changing fertility and oral contraceptive use. Br J Cancer 1995; 72(2): 485–492.

    Google Scholar 

  40. Buell P, Dunn JE. Cancer mortality among the Japanese Issei and Nisei of California. Cancer 1965; 18: 656–664.

    PubMed  CAS  Google Scholar 

  41. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999; 49(1): 8–31.

    PubMed  CAS  Google Scholar 

  42. Piffath TA, Whiteman MK, Flaws JA, Fix AD, Busht TL. Ethnic differences in cancer mortality trends in the US, 1950–1992. Ethn Health 2001; 6(2): 105–119.

    PubMed  CAS  Google Scholar 

  43. Oriel KA, Hartenbach EM, Remington PL. Trends in United States ovarian cancer mortality, 1979–1995. Obstet Gynecol 1999; 93(1): 30–33.

    PubMed  CAS  Google Scholar 

  44. Roush GC, Holford TR, Schymura MJ, White C. Cancer risk and incidence trends: the Connecticut perspective. Hemisphere, New York, 1987; 268–277.

    Google Scholar 

  45. Howe HL, Tung KH, Coughlin S, Jean-Baptiste R, Hotes J. Race/ethnic variations in ovarian cancer mortality in the United States, 1992–1997. Cancer 2003; 97(Suppl 10): 2686–2693.

    PubMed  Google Scholar 

  46. Greene MH, Clark JW, Blayney DW The epidemiology of ovarian cancer. Semin Oncol 1984; 11(3): 209–226.

    PubMed  CAS  Google Scholar 

  47. Rose DP, Boyar AP, Wynder EL. International comparisons of mortality rates for cancer of the breast, ovary, prostate, and colon, and per capita food consumption. Cancer 1986; 58(11): 2363–2371.

    PubMed  CAS  Google Scholar 

  48. Li FP, Shiang EL. Cancer mortality in China. J Natl Cancer Inst 1980; 65(2): 217–221.

    PubMed  CAS  Google Scholar 

  49. Cramer DW, Welch WR, Hutchison GB, Willett W, Scully RE. Dietary animal fat in relation to ovarian cancer risk. Obstet Gynecol 1984; 63(6): 833–838.

    PubMed  CAS  Google Scholar 

  50. Stocks P. Cancer mortality in relation to national consumption of cigarettes, solid fuel, tea and coffee. Br J Cancer 1970; 24(2): 215–225.

    PubMed  CAS  Google Scholar 

  51. Trichopoulos D, Papapostolou M, Polychronopoulou A. Coffee and ovarian cancer. Int J Cancer 1981; 28(6): 691–693.

    PubMed  CAS  Google Scholar 

  52. Byers T, Marshall J, Graham S, Mettlin C, Swanson M. A case-control study of dietary and nondietary factors in ovarian cancer. J Natl Cancer Inst 1983; 71(4): 681–686.

    PubMed  CAS  Google Scholar 

  53. Fairfield KM, Hankinson SE, Rosner BA, Hunter DJ, Colditz GA, Willett WC. Risk of ovarian carcinoma and consumption of vitamins A, C, and E and specific carotenoids: a prospective analysis. Cancer 2001; 92(9): 2318–2326.

    PubMed  CAS  Google Scholar 

  54. Venter PF. Ovarian epithelial cancer and chemical carcinogenesis. Gynecol Oncol 1981; 12(3): 281–285.

    PubMed  CAS  Google Scholar 

  55. Graham J, Graham R. Ovarian cancer and asbestos. Environ Res 1967; 1(2): 115–128.

    PubMed  CAS  Google Scholar 

  56. Henderson WJ, Hamilton TC, Griffiths K. Talc in normal and malignant ovarian tissue. Lancet 1979; 1(8114): 499.

    PubMed  CAS  Google Scholar 

  57. Keal EE. Asbestosis and abdominal neoplasms. Lancet 1960; 2: 1211–1216.

    PubMed  CAS  Google Scholar 

  58. Newhouse ML, Pearson RM, Fullerton JM, Boesen EA, Shannon HS. A case control study of carcinoma of the ovary. Br J Prev Soc Med 1977; 31(3): 148–153.

    PubMed  CAS  Google Scholar 

  59. Hartge P, Hoover R, Lesher LP, McGowan L. Talc and ovarian cancer. JAMA 1983; 250(14): 1844.

    PubMed  CAS  Google Scholar 

  60. Roe FJ. Controversy: cosmetic talc and ovarian cancer. Lancet 1979; 2(8145): 744.

    PubMed  CAS  Google Scholar 

  61. Whittemore AS, Wu ML, Paffenbarger RS Jr, et al. Personal and environmental characteristics related to epithelial ovarian cancer. II. Exposures to talcum powder, tobacco, alcohol, and coffee. Am J Epidemiol 1988; 128(6): 1228–1240.

    PubMed  CAS  Google Scholar 

  62. Cook LS, Kamb ML, Weiss NS. Perineal powder exposure and the risk of ovarian cancer. Am J Epidemiol 1997; 145(5): 459–465.

    PubMed  CAS  Google Scholar 

  63. Cramer DW, Welch WR, Scully RE, Wojciechowski CA. Ovarian cancer and talc: a case-control study. Cancer 1982; 50(2): 372–376.

    PubMed  CAS  Google Scholar 

  64. West RO. Epidemiologic study of malignancies of the ovaries. Cancer 1966; 19(7): 1001–1007.

    PubMed  CAS  Google Scholar 

  65. Menczer J, Modan M, Ranon L, Golan A. Possible role of mumps virus in the etiology of ovarian cancer. Cancer 1979; 43(4): 1375–1379.

    PubMed  CAS  Google Scholar 

  66. Cramer DW, Welch WR, Cassells S, Scully RE. Mumps, menarche, menopause, and ovarian cancer. Am J Obstet Gynecol 1983; 147(1): 1–6.

    PubMed  CAS  Google Scholar 

  67. Piver MS, Baker TR, Jishi MF, et al. Familial ovarian cancer-A report of 658 families from the Gilda Radner Familial Ovarian Cancer Registry 1981–1991. Cancer 1993; 71: 582–588.

    PubMed  CAS  Google Scholar 

  68. Plotkin SA, Wharton M. Mumps Vaccine. In: Vaccines (Plotkin SA, Orenstein WA, eds.), 3rd ed. Saunders, Philadelphia, 1999, pp. 267–292.

    Google Scholar 

  69. Peltola H, Heinonen OP, Valle M, et al. The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program. N Engl J Med 1994; 331(21): 1397–1402.

    PubMed  CAS  Google Scholar 

  70. Recommendations of the Immunization Practices Advisory Committee Mumps Prevention. MMWR 1989; 38(22): 388–400.

    Google Scholar 

  71. Kerlikowske K, Brown JS, Grady DG. Should women with familial ovarian cancer undergo prophylactic oophorectomy? Obstet Gynecol 1992; 80(4): 700–707.

    PubMed  CAS  Google Scholar 

  72. Schildkraut JM, Risch N, Thompson WD. Evaluating genetic association among ovarian, breast, and endometrial cancer: evidence for a breast/ovarian cancer relationship. Am J Hum Genet 1989; 45(4): 521–529.

    PubMed  CAS  Google Scholar 

  73. Houlston RS, Collins A, Slack J, et al. Genetic epidemiology of ovarian cancer: segregation analysis. Ann Hum Genet 1991; 55(Pt 4): 291–299.

    PubMed  CAS  Google Scholar 

  74. Bewtra C, Watson P, Conway T, Read-Hippee C, Lynch HT. Hereditary ovarian cancer: a clinicopathological study. Int J Gynecol Pathol 1992; 11(3): 180–187.

    PubMed  CAS  Google Scholar 

  75. Narod SA, Madlensky L, Bradley L, et al. Hereditary and familial ovarian cancer in southern Ontario. Cancer 1994; 74(8): 2341–2346.

    PubMed  CAS  Google Scholar 

  76. Lynch HT, Lynch JF, Conway TA. Hereditary ovarian cancer, in Ovarian Cancer (Rubin SC, Sutton GP, eds.), McGraw-Hill, New York, 1993, pp. 189–217.

    Google Scholar 

  77. Lynch HT, Harris RE, Guirgis HA, Maloney K, Carmody LL, Lynch JF. Familial association of breast/ovarian carcinoma. Cancer 1978; 41: 1543–1549.

    PubMed  CAS  Google Scholar 

  78. Easton DF, Bishop DT, Ford D, Crockford GP. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1993; 52(4): 678–701.

    PubMed  CAS  Google Scholar 

  79. Median Age at Diagnosis and Death, 1997–2001. Surveillance, Epidemiology, and End Results, National Cancer Institute, 2004 (Accessed at http://seer.cancer.gov/csr/1975_2001/sections.html).

  80. Robson M, Holcombe T, McCormick B, et al. Feasibility of breast conserving treatment for breast cancer in women with germline BRCA mutations: A clinic-based series. / Clin Oncol (Asco Ann Proc) 22(145, suppl): 9618.

    Google Scholar 

  81. Rubin SC, Benjamin I, Behbakht K, et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med 1996; 335(19): 1413–1416.

    PubMed  CAS  Google Scholar 

  82. Fasouliotis SJ, Schenker JG. BRCA1 and BRCA2 gene mutations: decision-making dilemmas concerning testing and management. Obstet Gynecol Surv 2000; 55(6): 373–384.

    PubMed  CAS  Google Scholar 

  83. DiSaia PJ, Creasman WT. Epithelial Ovarian Cancer, in Clinical Gynecologic Oncology (DiSaia PJ, Creasman WT, eds.), Mosby, St. Louis, MO, 1997, pp. 282–350.

    Google Scholar 

  84. Hall JM, Lee MK, Newman B, et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 1990; 250(4988): 1684–1689.

    PubMed  CAS  Google Scholar 

  85. Steichen-Gersdorf E, Gallion HH, Ford D, et al. Familial site-specific ovarian cancer is linked to BRCA1 on 17ql2-21. Am J Hum Genet 1994; 55(5): 870–875.

    PubMed  CAS  Google Scholar 

  86. Merajver SD, Frank TS, Xu J, et al. Germline BRCA1 mutations and loss of the wild-type allele in tumors from families with early onset breast and ovarian cancer. Clin Cancer Res 1995; 1(5): 539–544.

    PubMed  CAS  Google Scholar 

  87. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266(5182): 66–71.

    PubMed  CAS  Google Scholar 

  88. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378(6559): 789–792.

    PubMed  CAS  Google Scholar 

  89. Berchuck A, Cirisano F, Lancaster JM, et al. Role of BRCA1 mutation screening in the management of familial ovarian cancer. Am J Obstet Gynecol 1996; 175(3 Pt 1): 738–746.

    PubMed  CAS  Google Scholar 

  90. Takahashi H, Behbakht K, McGovern PE, et al. Mutation analysis of the BRCA1 gene in ovarian cancers. Cancer Res 1995; 55(14): 2998–3002.

    PubMed  CAS  Google Scholar 

  91. Newman B, Mu H, Butler LM, Millikan RC, Moorman PG, King MC. Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. JAMA 1998; 279(12): 915–921.

    PubMed  CAS  Google Scholar 

  92. Couch FJ, Hartmann LC. BRCA1 testing—advances and retreats. JAMA 1998; 279(12): 955–957.

    PubMed  CAS  Google Scholar 

  93. Malone KE, Daling JR, Thompson JD, O’Brien CA, Francisco LV, Ostrander EA. BRCA1 mutations and breast cancer in the general population: analyses in women before age 35 years and in women before age 45 years with first-degree family history. JAMA 1998; 279(12): 922–929.

    PubMed  CAS  Google Scholar 

  94. Moslehi R, Chu W, Karlan B, et al. BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet 2000; 66(4): 1259–1272.

    PubMed  CAS  Google Scholar 

  95. Boyd J, Sonoda Y, Federici MG, et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 2000; 283(17): 2260–2265.

    PubMed  CAS  Google Scholar 

  96. Robson M, Levin D, Federici M, et al. Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations. J Natl Cancer Inst 1999; 91(24): 2112–2117.

    PubMed  CAS  Google Scholar 

  97. Fodor FH, Weston A, Bleiweiss IJ, et al. Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients. Am J Hum Genet 1998; 63(1): 45–51.

    PubMed  CAS  Google Scholar 

  98. Suzuki A, de la Pompa JL, Hakem R, et al. BRCA2 is required for embryonic cellular proliferation in the mouse. Genes Dev 1997; 11(10): 1242–1252.

    PubMed  CAS  Google Scholar 

  99. Hakem R, de la Pompa JL, Mak TW. Developmental studies of BRCA1 and BRCA2 knock-out mice. J Mammary Gland Biol Neoplasia 1998; 3(4): 431–445.

    PubMed  CAS  Google Scholar 

  100. Hakem R, de la Pompa JL, Sirard C, et al. The tumor suppressor gene BRCA1 is required for embryonic cellular proliferation in the mouse. Cell 1996; 85(7): 1009–1023.

    PubMed  CAS  Google Scholar 

  101. Smith PD, Crossland S, Parker G, et al. Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions. Oncogene 1999; 18(15): 2451–2459.

    PubMed  CAS  Google Scholar 

  102. Crook T, Brooks LA, Crossland S, et al. p53 mutation with frequent novel condons but not a mutator phenotype in BRCA1-and BRCA2-associated breast tumours. Oncogene 1998; 17(13): 1681–1689.

    PubMed  CAS  Google Scholar 

  103. Crook T, Crossland S, Crompton MR, Osin P, Gusterson BA. p53 mutations in BRCA1-associated familial breast cancer. Lancet 1997; 350(9078): 638–639.

    PubMed  CAS  Google Scholar 

  104. Powell SN, Kachnic LA. Roles of BRCA1 and BRCA2 in homologous recombination, DNA replication fidelity and the cellular response to ionizing radiation. Oncogene 2003; 22(37): 5784–5791.

    PubMed  CAS  Google Scholar 

  105. Kinzler KW, Vogelstein B. Cancer-susceptibility genes. Gatekeepers and caretakers. Nature 1997; 386(6627): 761–763.

    PubMed  CAS  Google Scholar 

  106. Patel KJ, Yu VP, Lee H, et al. Involvement of Brca2 in DNA repair. Mol Cell 1998; 1(3): 347–357.

    PubMed  CAS  Google Scholar 

  107. Tirkkonen M, Johannsson O, Agnarsson BA, et al. Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res 1997; 57(7): 1222–1227.

    PubMed  CAS  Google Scholar 

  108. Gretarsdottir S, Thorlacius S, Valgardsdottir R, et al. BRCA2 and p53 mutations in primary breast cancer in relation to genetic instability. Cancer Res 1998; 58(5): 859–862.

    PubMed  CAS  Google Scholar 

  109. Xu X, Wagner KU, Larson D, et al. Conditional mutation of Brcal in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat Genet 1999; 22(1): 37–43.

    PubMed  CAS  Google Scholar 

  110. Goodman MF. Coping with replication “train wrecks” in Escherichia coli using Pol V, Pol II and RecA proteins. Trends Biochem Sci 2000; 25(4): 189–195.

    PubMed  CAS  Google Scholar 

  111. Chen J, Silver DP, Walpita D, et al. Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells. Mol Cell 1998; 2(3): 317–328.

    PubMed  CAS  Google Scholar 

  112. Chen PL, Chen CF, Chen Y, Xiao J, Sharp ZD, Lee WH. The BRC repeats in BRCA2 are critical for RAD51 binding and resistance to methyl methanesulfonate treatment. Proc Natl Acad Sci USA 1998; 95(9): 5287–5292.

    PubMed  CAS  Google Scholar 

  113. Davies AA, Masson JY, Mcllwraith MJ, et al. Role of BRCA2 in control of the RAD51 recombination and DNA repair protein. Mol Cell 2001; 7(2): 273–282.

    PubMed  CAS  Google Scholar 

  114. Snouwaert JN, Gowen LC, Latour AM, et al. BRC Al deficient embryonic stem cells display a decreased homologous recombination frequency and an increased frequency of non-homologous recombination that is corrected by expression of a brcal transgene. Oncogene 1999; 18(55): 7900–7907.

    PubMed  CAS  Google Scholar 

  115. Moynahan ME, Cui TY, Jasin M. Homology-directed dna repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brcal mutation. Cancer Res 2001; 61(12): 4842–4850.

    PubMed  CAS  Google Scholar 

  116. Xu B, Kim S, Kastan MB. Involvement of Brcal in S-phase and G(2)-phase checkpoints after ionizing irradiation. Mol Cell Biol 2001; 21(10): 3445–3450.

    PubMed  CAS  Google Scholar 

  117. Kraakman-van der Zwet M, Overkamp WJ, van Lange RE, et al. Brca2 (XRCC11) deficiency results in radioresistant DNA synthesis and a higher frequency of spontaneous deletions. Mol Cell Biol 2002; 22(2): 669–679.

    Google Scholar 

  118. Xu X, Weaver Z, Linke SP, et al. Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Mol Cell 1999; 3(3): 389–395.

    PubMed  CAS  Google Scholar 

  119. Chen CF, Chen PL, Zhong Q, Sharp ZD, Lee WH. Expression of BRC repeats in breast cancer cells disrupts the BRCA2-Rad51 complex and leads to radiation hypersensitivity and loss of G(2)/M checkpoint control. J Biol Chem 1999; 274(46): 32,931–32,935.

    PubMed  CAS  Google Scholar 

  120. Xu B, O’Donnell AH, Kim ST, Kastan MB. Phosphorylation of serine 1387 in BRCA1 is specifically required for the Atm-mediated S-phase checkpoint after ionizing irradiation. Cancer Res 2002; 62(16): 4588–4591.

    PubMed  CAS  Google Scholar 

  121. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998; 62(3): 676–689.

    PubMed  CAS  Google Scholar 

  122. Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 2002; 94(18): 1365–1372.

    PubMed  CAS  Google Scholar 

  123. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997; 336(20): 1401–1408.

    PubMed  CAS  Google Scholar 

  124. Satagopan JM, Offit K, Foulkes W, et al. The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomarkers Prev 2001; 10(5): 467–473.

    PubMed  CAS  Google Scholar 

  125. Risch HA, McLaughlin JR, Cole DE, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001; 68(3): 700–710.

    PubMed  CAS  Google Scholar 

  126. Satagopan JM, Boyd J, Kauff ND, et al. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Clin Cancer Res 2002; 8(12): 3776–3781.

    PubMed  CAS  Google Scholar 

  127. Moller P, Borg A, Evans DG, et al. Survival in prospectively ascertained familial breast cancer: analysis of a series stratified by tumour characteristics, BRCA mutations and oophorectomy. Int J Cancer 2002; 101(6): 555–559.

    PubMed  CAS  Google Scholar 

  128. Burke W, Petersen G, Lynch P, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. I. Hereditary nonpolyposis colon cancer. Cancer Genetics Studies Consortium. JAMA 1997; 277(11): 915–919.

    PubMed  CAS  Google Scholar 

  129. Aarnio M, Mecklin JP, Aaltonen LA, Nystrom-Lahti M, Jarvinen HJ. Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int J Cancer 1995; 64(6): 430–433.

    PubMed  CAS  Google Scholar 

  130. Aarnio M, Sankila R, Pukkala E, et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 1999; 81(2): 214–218.

    PubMed  CAS  Google Scholar 

  131. Dunlop MG, Farrington SM, Carothers AD, et al. Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet 1997; 6(1): 105–110.

    PubMed  CAS  Google Scholar 

  132. Vasen HF, Wijnen JT, Menko FH, et al. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 1996; 110(4): 1020–1027.

    PubMed  CAS  Google Scholar 

  133. Watson P, Lynch HT. Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer 1993; 71(3): 677–685.

    PubMed  CAS  Google Scholar 

  134. Aaltonen LA, Peltomaki P, Leach FS, et al. Clues to the pathogenesis of familial colorectal cancer. Science 1993; 260(5109): 812–816.

    PubMed  CAS  Google Scholar 

  135. Leach FS, Nicolaides NC, Papadopoulos N, et al. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 1993; 75(6): 1215–1225.

    PubMed  CAS  Google Scholar 

  136. Risinger JI, Berchuck A, Kohler MF, Watson P, Lynch HT, Boyd J. Genetic instability of microsatellites in endometrial carcinoma. Cancer Res 1993; 53(21): 5100–5103.

    PubMed  CAS  Google Scholar 

  137. Bellacosa A, Genuardi M, Anti M, Viel A, Ponz de Leon M. Hereditary nonpolyposis colorectal cancer: review of clinical, molecular genetics, and counseling aspects. Am J Med Genet 1996; 62(4): 353–364.

    PubMed  CAS  Google Scholar 

  138. Samowitz WS, Curtin K, Lin HH, et al. The colon cancer burden of genetically defined hereditary nonpolyposis colon cancer. Gastroenterology 2001; 121(4): 830–838.

    PubMed  CAS  Google Scholar 

  139. Percesepe A, Borghi F, Menigatti M, et al. Molecular screening for hereditary nonpolyposis colorectal cancer: a prospective, population-based study. J Clin Oncol 2001; 19(19): 3944–3950.

    PubMed  CAS  Google Scholar 

  140. Salovaara R, Loukola A, Kristo P, et al. Population-based molecular detection of hereditary nonpolyposis colorectal cancer. J Clin Oncol 2000; 18(11): 2193–2200.

    PubMed  CAS  Google Scholar 

  141. Tinley ST, Lynch HT. Integration of family history and medical management of patients with hereditary cancers. Cancer 1999; 86(Suppl 11): 2525–2532.

    PubMed  CAS  Google Scholar 

  142. Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, Adopted on February 20, 1996. J Clin Oncol 1996; 14(5): 1730–1736, discussion 1737-1740.

    Google Scholar 

  143. Frank TS, Manley SA, Olopade OI, et al. Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol 1998; 16(7): 2417–2425.

    PubMed  CAS  Google Scholar 

  144. Couch FJ, DeShano ML, Blackwood MA, et al. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 1997; 336(20): 1409–1415.

    PubMed  CAS  Google Scholar 

  145. Burke W, Daly M, Garber J, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA 1997; 277(12): 997–1003.

    PubMed  CAS  Google Scholar 

  146. Mackey SE, Creasman WT. Ovarian cancer screening. J Clin Oncol 1995; 13(3): 783–793.

    PubMed  CAS  Google Scholar 

  147. NIH consensus conference. Ovarian cancer. Screening, treatment, and follow-up. NIH Consensus Development Panel on Ovarian Cancer. JAMA 1995; 273(6): 491–497

    Google Scholar 

  148. Skates SJ, Pauler DK, Jacobs IJ. Screening based on the risk of cancer calculation from bayesian hierarchical changepoint and mixture models of longitudinal markers. J Am Stat Assoc 2001; 96: 429.

    Google Scholar 

  149. van Nagell JR Jr, DePriest PD, Reedy MB, et al. The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecol Oncol 2000; 77(3): 350–356.

    PubMed  Google Scholar 

  150. Jacobs IJ, Skates S, Davies AP, et al. Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration: a prospective cohort study. BMJ 1996; 313(7069): 1355–1358.

    PubMed  CAS  Google Scholar 

  151. van Nagell JR Jr, Gallion HH, Pavlik EJ, DePriest PD. Ovarian cancer screening. Cancer 1995; 76(Suppl 10): 2086–2091.

    PubMed  Google Scholar 

  152. Botkin JR, Smith KR, Croyle RT, et al. Genetic testing for a BRCA1 mutation: Prophylactic surgery and screening behavior in women 2 years post testing. Am J Med Genet 2003; 118A(3): 201–209.

    Google Scholar 

  153. Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002; 359(9306): 572–577.

    PubMed  CAS  Google Scholar 

  154. Modan B, Hartge P, Hirsh-Yechezkel G, et al. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med 2001; 345(4): 235–240.

    PubMed  CAS  Google Scholar 

  155. Rosenberg L, Palmer JR, Zauber AG, et al. A case-control study of oral contraceptive use and invasive epithelial ovarian cancer. Am J Epidemiol 1994; 139(7): 654–661.

    PubMed  CAS  Google Scholar 

  156. Schildkraut JM, Calingaert B, Marchbanks PA, Moorman PG, Rodriguez GC. Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk. J Natl Cancer Inst 2002; 94(1): 32–38.

    PubMed  CAS  Google Scholar 

  157. Rodriguez GC, Nagarsheth NP, Lee KL, et al. Progestin-induced apoptosis in the Macaque ovarian epithelium: differential regulation of transforming growth factor-beta. J Natl Cancer Inst 2002; 94(1): 50–60.

    PubMed  CAS  Google Scholar 

  158. Rodriguez GC, Walmer DK, Cline M, et al. Effect of progestin on the ovarian epithelium of macques: cancer prevention through apoptosis? J Soc Gynecol Invest 1998; 5: 271–276.

    CAS  Google Scholar 

  159. Brewer MA, Mitchell MF, Bast RC. Prevention of ovarian cancer. In Vivo 1999; 13(1): 99–106.

    PubMed  CAS  Google Scholar 

  160. Zhang D, Holmes WF, Wu S, Soprano DR, Soprano KJ. Retinoids and ovarian cancer. J Cell Physiol 2000; 185(1): 1–20.

    PubMed  CAS  Google Scholar 

  161. Formelli F, Cleris L. Synthetic retinoid fenretinide is effective against a human ovarian carcinoma xenograft and potentiates cisplatin activity. Cancer Res 1993; 53(22): 5374–5376.

    PubMed  CAS  Google Scholar 

  162. Supino R, Crosti M, Clerici M, et al. Induction of apoptosis by fenretinide (4HPR) in human ovarian carcinoma cells and its association with retinoic acid receptor expression. Int J Cancer 1996; 65(4): 491–497.

    PubMed  CAS  Google Scholar 

  163. Sabichi AL, Hendricks DT, Bober MA, Birrer MJ. Retinoic acid receptor beta expression and growth inhibition of gynecologic cancer cells by the synthetic retinoid N-(4-hydroxyphenyl) retinamide. J Natl Cancer Inst 1998; 90(8): 597–605.

    PubMed  CAS  Google Scholar 

  164. De Palo G, Camerini T, Marubini E, et al. Chemoprevention trial of contralateral breast cancer with fenretinide. Rationale, design, methodology, organization, data management, statistics and accrual. Tumori 1997; 83(6): 884–894.

    PubMed  CAS  Google Scholar 

  165. Devesa SS, Grauman DJ, Blot WJ, Pennello G, Hoover RN, Fraumeni JF Jr. Atlas of Cancer Mortality in the US: 1950–1994. NIH Publication No. 99-4564, Washington, DC, US Govt Print Off, 1999.

    Google Scholar 

  166. Ferlay Bray F, Pisani P, Parkin DM. GLOBOCAN 2000: Cancer incidence, mortality and prevalence worldwide, Version 1.0 ed. Lyon: IARC Press; 2001.

    Google Scholar 

  167. Lefkowitz ES, Garland CF. Sunlight, vitamin D, and ovarian cancer mortality rates in US women. Int J Epidemiol 1994; 23(6): 1133–1136.

    PubMed  CAS  Google Scholar 

  168. Schwartz GG, Hulka BS. Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res 1990; 10(5 A): 1307–1311.

    PubMed  CAS  Google Scholar 

  169. Corder EH, Guess HA, HuLka BS, et al. Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol Biomarkers Prev 1993; 2(5): 467–472.

    PubMed  CAS  Google Scholar 

  170. Schwartz GG, Oeler TA, Uskokovic MR, Bahnson RR. Human prostate cancer cells: inhibition of proliferation by vitamin D analogs. Anticancer Res 1994; 14(3A): 1077–1081.

    PubMed  CAS  Google Scholar 

  171. Design of the Women’s Health Initiative clinical trial and observational study. The Women’s Health Initiative Study Group. Control Clin Trials 1998; 19(1): 61–109.

    Google Scholar 

  172. Cramer DW, Harlow BL, Titus-Ernstoff L, Bohlke K, Welch WR, Greenberg ER. Over-the-counter analgesics and risk of ovarian cancer. Lancet 1998; 351(9096): 104–107.

    PubMed  CAS  Google Scholar 

  173. Moysich KB, Mettlin C, Piver MS, Natarajan N, Menezes RJ, Swede H. Regular use of analgesic drugs and ovarian cancer risk. Cancer Epidemiol Biomarkers Prev 2001; 10(8): 903–906.

    PubMed  CAS  Google Scholar 

  174. Rosenberg L, Palmer JR, Rao RS, et al. A case-control study of analgesic use and ovarian cancer. Cancer Epidemiol Biomarkers Prev 2000; 9(9): 933–937.

    PubMed  CAS  Google Scholar 

  175. Tavani A, Gallus S, La Vecchia C, Conti E, Montella M, Franceschi S. Aspirin and ovarian cancer: an Italian case-control study. Ann Oncol 2000; 11(9): 1171–1173.

    PubMed  CAS  Google Scholar 

  176. Akhmedkhanov A, Toniolo P, Zeleniuch-Jacquotte A, Kato I, Koenig KL, Shore RE. Aspirin and epithelial ovarian cancer. Prev Med 2001; 33(6): 682–687.

    PubMed  CAS  Google Scholar 

  177. Rodriguez-Burford C, Barnes MN, Oelschlager DK, et al. Effects of nonsteroidal anti-inflammatory agents (NSAIDs) on ovarian carcinoma cell lines: preclinical evaluation of NSAIDs as chemopreventive agents. Clin Cancer Res 2002; 8(1): 202–209.

    PubMed  CAS  Google Scholar 

  178. Xu XC. COX-2 inhibitors in cancer treatment and prevention, a recent development. Anticancer Drugs 2002; 13(2): 127–137.

    PubMed  Google Scholar 

  179. Dannenberg AJ, Altorki NK, Boyle JO, et al. Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol 2001; 2(9): 544–551.

    PubMed  CAS  Google Scholar 

  180. Smith ER, Daly MB, Xu XX. A mechanism for cox-2 inhibitor anti-inflammatory activity in chemoprevention of epithelial cancers. Cancer Epidemiol Biomarkers Prev 2004; 13(1): 144–145.

    PubMed  CAS  Google Scholar 

  181. Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engt J Med 2002; 346(21): 1616–1622.

    Google Scholar 

  182. Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCAl or BRCA2 mutation. N Engl J Med 2002; 346(21): 1609–1615.

    PubMed  Google Scholar 

  183. Tobacman JK, Greene MH, Tucker MA, Costa J, Kase R, Fraumeni JF, Jr. Intra-abdominal carcinomatosis after prophylactic oophorectomy in ovarian-cancer-prone families. Lancet 1982; 2(8302): 795–797.

    PubMed  CAS  Google Scholar 

  184. Scheuer L, Kauff N, Robson M, et al. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol 2002; 20(5): 1260–1268.

    PubMed  Google Scholar 

  185. Colgan TJ, Murphy J, Cole DE, Narod S, Rosen B. Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am J Surg Pathol 2001; 25(10): 1283–1289.

    PubMed  CAS  Google Scholar 

  186. Lu KH, Garber JE, Cramer DW, et al. Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. J Clin Oncol 2000; 18(14): 2728–2732.

    PubMed  CAS  Google Scholar 

  187. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994; 86(7): 527–537.

    PubMed  CAS  Google Scholar 

  188. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-l Study. J Natl Cancer Inst 1998; 90(18): 1371–1388.

    PubMed  CAS  Google Scholar 

  189. Meijers-Heijboer H, Brekelmans CT, Menke-Pluymers M, et al. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation. J Clin Oncol 2003; 21(9): 1675–1681.

    PubMed  Google Scholar 

  190. Tiller K, Meiser B, Butow P, et al. Psychological impact of prophylactic oophorectomy in women at increased risk of developing ovarian cancer: a prospective study. Gynecol Oncol 2002; 86(2): 212–219.

    PubMed  CAS  Google Scholar 

  191. Boyd J. Molecular genetics of hereditary ovarian cancer. Oncology (Huntingt) 1998; 12(3): 399–406; discussion 409-310.

    PubMed  CAS  Google Scholar 

  192. Lynch HT, Schuelke GS, Kimberling WJ, et al. Hereditary nonpolyposis colorectal cancer (Lynch syndromes I and II). II. Biomarker studies. Cancer 1985; 56(4): 939–951.

    PubMed  CAS  Google Scholar 

  193. Lynch HT, Kimberling W, Albano WA, et al. Hereditary nonpolyposis colorectal cancer (Lynch syndromes I and II). I. Clinical description of resource. Cancer 1985; 56(4): 934–938.

    PubMed  CAS  Google Scholar 

  194. Boyd J. Molecular genetics of hereditary ovarian cancer, in Ovarian Cancer (Rubin SC, Sutton GP, eds.), 2nd ed., Williams & Wilkins, Lippincott, Philadelphia, 2001, pp. 3–22.

    Google Scholar 

  195. Shattuck-Eidens D, Oliphant A, McClure M, et al. BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA 1997; 278(15): 1242–1250.

    PubMed  CAS  Google Scholar 

  196. Levine DA, Gemignani ML. Prophylactic surgery in hereditary breast/ovarian cancer syndrome. Oncology (Huntingt) 2003; 17(7): 932–941; discussion 946-948, 950-952.

    PubMed  Google Scholar 

  197. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 1995; 56(1): 265–271.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Pennsylvania Medical Center, Philadelphia, PA

    Christina S. Chu MD & Stephen C. Rubin MD

Authors
  1. Christina S. Chu MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephen C. Rubin MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Sbarro Institute for Cancer Research and Molecular Medicine, Temple University, Philadelphia, PA

    Antonio Giordano MD, PhD  & Alessandro Bovicelli MD, PhD  & 

  2. Departments of Human Pathology and Oncology, University of Siena, Siena, Italy

    Antonio Giordano MD, PhD

  3. Department of Obstetrics and Gynecology, University of Bologna, Bologna, Italy

    Alessandro Bovicelli MD, PhD

  4. Departments of Gynecology-Obstetrics and Pathology, Johns Hopkins University, Baltimore, MD

    Robert J. Kurman MD, PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Chu, C.S., Rubin, S.C. (2007). Hereditary Issues In Ovarian Cancer. In: Giordano, A., Bovicelli, A., Kurman, R.J. (eds) Molecular Pathology of Gynecologic Cancer. Current Clinical Oncology. Humana Press. https://doi.org/10.1007/978-1-59745-346-2_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-346-2_11

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-453-1

  • Online ISBN: 978-1-59745-346-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation